Bavarian Nordic to begin melanoma trial

Bavarian Nordic Research Institute (CSE:BNRI) will begin a Phase I/II trial in Italy of its MVA-F6 tyrosinase immunotherapy to treat metastatic malignant melanoma. Tyrosinase is an enzyme involved in ...